Grace Therapeutics Announces Third Fiscal Quarter 2025 Financial Results, Provides Business Update
Announced Phase 3 STRIVE-ON Safety Trial Met Primary Endpoint and Provided Clinical Benefit Compared to Orally Administered Nimodipine; New Drug ...
Grace Therapeutics, Inc.: Grace Therapeutics Announces Third Fiscal Quarter 2025 Financial Results, Provides Business Update
Announced Phase 3 STRIVE-ON Safety Trial Met Primary Endpoint and Provided Clinical Benefit Compared to Orally Administered Nimodipine; New Drug Application (NDA) Submission Anticipated First Half of ...
SCLX Stock Touches 52-Week Low at $0.33 Amid Market Challenges
In a turbulent market environment, SCLX stock has reached a 52-week low, trading at $0.33, with a market capitalization of $62.12 million. This price level reflects a significant downturn for the ...